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1 Introduction 
In humans and other higher primates, uric acid (UA) is the end product of purine 
metabolism generated by oxidation of xanthine catalyzed by xantine oxidase (XO) (EC 
1.17.3.2) (Figure 1). In other mammals, UA is further oxidized by uricase (EC 1.7.3.3) to yield 
highly soluble allantoin, which is then excreted from the body. From the evolutionary 
standpoint, the reasons for the mutations resulting in a nonfunctioning uricase gene 
(pseudogene) in higher mammals are still unclear. In contrast to allantoin, uric acid is poorly 
hydrosoluble (water solubility of its salts, the urates, is slightly higher) and when its serum 
concentrations exceed the theoretical limit of solubility (around 415 mol/L, or 7 mg/dL), 
urate crystals are likely to be formed. Approximately two thirds of the daily UA turnover is 
eliminated by the kidney (glomerular filtration, tubular re-absorption and secretion) and 
one third via the gastrointestinal system. 
Xanthine oxidase is an ubiquitous enzyme, distributed in the liver (particularly), gut 
(particularly), kidney, heart (capillary endothelium primarily, but has been proven in 
cardiomyocytes, as well), brain, as well as in plasma. Besides the conversion of 
hypoxanthine to xanthine and xanthine to UA, it has a number of other functions, including 
hydroxylation of various purines, pterins, aromatic heterocycles and aliphatic and aromatic 
aldehydes (for a detailed review on XO see Pacher et al., 2006). Serum levels of UA (serum 
uric acid, SUA) are governed by the rates of its production and elimination, and are 
susceptible to a variety of nutritional, genetic, pharmacological and morbidity influences 
(Table 1). Hyperuricemia, a state of overtly high SUA concentration, is typically defined as 
SUA >360 µmol/L in women and >420 µmol/L in men, whereas values 310-420 µmol/L in 
men and 250-360 µmol/L in women are conventionally considered as “high-normal“. 
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Fig. 1. Metabolism of uric acid. 
*Dietary factors: increased purine intake in animal products especially internal organs 
(liver, kidney, brain, meat extracts), sweetbreads, anchovies, sardines, herring, mackerel, 
game meats, gravy, high fructose intake, alcohol 
*Reduced excretion by diseased kidneys 
*Malignancies, polycythemia vera, myelodysplastic syndromes, hemolytic anemias or 
other conditions with a rapid cell turnover 
*Use of diuretics 
*Mutations in proteins involved in the urate metabolism, especially xanthine oxidase, 
urate transporter/channel (UAT), organic anion transporters 1 and 3 (OAT1 and OAT3) 
and urate transporter 1 (URAT1) 
Table 1. The main causes of hyperuricemia (after Lippi et al., 2008)  
Ever since the late 19th century, and particularly since the 1950s, the potential role of SUA, 
specifically, increased SUA in cardiovascular diseases (CVD) has attracted much attention. 
A plethora of non-clinical, clinical and epidemiological studies have accumulated over the 
decades that aimed to elucidate molecular and cellular mechanisms of UA and the role of 
SUA as a diagnostic or a prognostic aid, or as a therapeutic target. Uric acid has a number of 
molecular effects potentially interesting in respect to CVD. One of the first recognized was 
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the antioxidant potential of UA – together with ascorbic acid which recycles the UA radicals, 
it is the most important antioxidant in plasma that effectively scavenges the superoxide 
anion, hydroxyl radicals and singlet oxygen and may chelate transitional metals. 
Furthermore, UA blocks the reaction in which peroxynitrite (generated in reactions by 
which superoxide anion inactivates nitric oxide, NO) attacks and nitrosylates tyrosine 
residues in various proteins. Moreover, UA inhibits degradation of the extracellular 
superoxide dismutase (SOD3), which then is able to convert superoxide anion into hydrogen 
peroxide, and thus prevent NO inactivation (by the superoxide anion). Based on the 
knowledge about the role of oxidative stress in various aspects of CVD (e.g., endothelial 
function, myocardial function), it has been suggested that the loss of uricase activity in 
humans should be viewed as an “evolutionary benefit”, protective of the cardiovascular 
system. Indeed, there is solid evidence that a transient rise in SUA reduces markers of 
oxidative stress, which then correlates well with improvements in some of the indices of 
cardiovascular function. For example, it has been rather well elaborated that the 
cardiovascular benefit of moderate wine drinking (with food) is largely due to an acute and 
transient wine-induced rise in SUA that counter-acts the food-induced oxidative stress. 
However, prolonged/excessive increase in SUA is clearly associated with cardiovascular 
risks or “damage” (see below), rather than with a cardiovascular benefit. Although we are 
still far from full understanding of molecular/cellular mechanisms of UA, the knowledge is 
extensive and some effects have been well documented and provide a sound mechanistic 
rationale. As most of the other antioxidants, under certain conditions (e.g., high 
concentrations, low pH, like in hypoxic tissues, low levels of other antioxidants) UA may 
promote oxidative stress. For example, it depletes ascorbic acid (used to re-cycle UA 
radicals), and thus reduces re-cycling of -tocopherol and, consequently, -carotene, other 
potent antioxidants, which, overall, may results in a reduced antioxidant activity. In vitro, 
UA (but not its precursors xanthine and hypoxanthine) exerts a number of effects on 
vascular smooth muscle cells: enters the cells via organic anionic transporters and activates 
transcriptional factors, like nuclear factor kappa B (NF-B) and activation protein 1 (AP-1); 
induces the tissue renin-angiotensin-aldosterone system and angitensin II production; 
induces cell proliferation (via MAPK and Erk1/2 kinases); induces COX2 activity and 
thromboxane synthesis; induces synthesis of the monocytic chemoatractant protein 1 (MCP-
1, via p38 MAPK) which is important in the pathogenesis of atherosclerosis; induces 
production of c-reactive protein (CRP) (via p38 MAPK). Uric acid also stimulates the 
mononuclear cells to production of interleukin (IL)-1, IL-6 and tumor necrosis factor- 
(TNF-). Clearly, UA may recruit a whole armamentarium of molecular/cellular “players” 
that are known to be involved in the pathophysiology of vascular changes underlying CVD. 
Indeed, it has been repeatedly shown that infusion of UA in humans induces platelet 
aggregation and endothelial dysfunction with reduced NO production, an effect also seen 
within the kidneys. However, when discussing the potential role of UA as a “direct 
pathogen” in CVD, one should also keep in mind that, inherently, SUA levels are a marker 
of the activity of XO, an enzyme that per se has an important role in the oxidant-antioxidant 
system. While measuring SUA in humans is simple, accurate and cheap, there is no routine 
method to directly measure XO activity. Xanthine oxidase has been strongly implicated in 
CVD. The enzyme is expressed in the endothelium, but it is generally thought that XO 
released from the liver and the gut into the circulation and then bound to the endothelial cell 
is the important factor. It is in a complex relationship with NO – XO generates superoxide 
anion (e.g., during xanthine oxidation) that inactivates NO and tonically suppress NO 
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synthase (NOs), whereas conversely, NO may suppress XO activity and XO is also capable 
of reducing nitrates and nitrites back to NO. As already mentioned, superoxide-NO 
reactions and reactions between the superoxide and various nitrosothiols generate 
peroxynitrite that can inflict oxidative and nitrosative injury to proteins, enzymes, lipids, 
DNA. There are observations regarding endothelial dysfunction that “shift” the focus from 
SUA itself to XO – while infusion of UA may induce it, uriocosuric agents, that reduce SUA, 
have failed to improve endothelial function; on the other hand, XO inhibitors (like 
allopurinol) improve the disrupted endothelial function even before changes in SUA occur. 
Therefore, considerations of “elevated SUA” and its role in CVD inevitably subsume its 
potential direct effector mechanisms, but also those effects of XO which are UA-independent 
and for which elevated SUA is (just) a marker. 
Over the decades, at the clinical and epidemiological level, the “issue” of (S)UA and CVD 
has been encompassed by a controversy – should the relationship be perceived as a causative 
one, or as a mere association? In part, it has been fuelled by the mechanistic knowledge about 
the direct (possible) deleterious effects of UA and the fact that, at the same time, it might be 
just a marker of other events (e.g., XO activity). Additional contribution to the controversy 
comes from the inconsistency of observations (both “negative” and “positive” observations 
in many settings) and the nature of (some of) the clinical/epidemiological observations. 
First, SUA has been related not only to CVD or its “endpoint-events”, like development of 
coronary artery disease (CAD) and related mortality, chronic heart failure, acute myocardial 
infarction or stroke, but also to a number of conditions that per se are CVD risk factors, e.g., 
hypertension, glucose intolerance, insulin resistance, dyslipidemia, obesity, metabolic 
syndrome, renal failure. Second, some of the studies were conducted in a way that allowed 
only for detection of associations, which were frequently difficult to interpret. For example, 
in some cases it was not possible to “isolate” an independent relationship (association) 
(independent of other risk factors) between SUA and the end point, either a direct one (of 
the type SUA  endpoint) or a mediated one (of the type SUA  other risk factor  
endpoint). Furthermore, the interpretation of associations in terms of “causes and 
consequences” is frequently complexed by the fact that both is possible, e.g., while there is 
evidence that hyperuricemia may promote renal failure, renal failure inevitably results in 
hyperuricemia. Generally, in biomedicine, the dilemma about causation vs. association has 
important practical implications – if a causative relationship is established between 
variables, then the “cause” clearly is a potential target for an intervention (preventive, 
therapeutic). It is the opinion of the authors of this text that in the specific case of SUA and 
CVD, this dilemma might not be as relevant. First, if there is a “marker” that can be 
determined easily, reproducibly and accurately and at low cost (SUA), that independently, 
consistently and accurately predicts future events (a reliable predictor), than, irrespective of 
the nature of its relationship with these “future events”, it per se is valuable (assessment of 
risk). One could easily agree that despite all the existing knowledge, there is still space for 
improvements in risk assessment in CVD. Next, considering the nature of a potential 
intervention (inhibition of XO, e.g., allopurinol), it seems irrelevant whether UA itself is a 
cause (acting directly on the endpoint variable, or through “intervening” or “mediation” 
variables [other risk factors], of both) or just a marker of increased XO activity, which in fact, 
is the cause (or – both!) – the intervention is likely to yield a benefit. It is far beyond the 
scope of this text to discuss in detail all the aspects of the complex relationship between SUA 
and CVD. For this purpose, reader is referred to comprehensive reviews on the topic, some 
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of which are listed at the end of this chapter (Johnson at al., 2003, Baker et al., 2005, 
Duan&Ling 2008, Naquibullah et al., 2007, Lippi et al., 2008, Feig et al., 2008, Doehner et al., 
2008, Gagliardi et al., 2009, Bergamini et al., 2009, Kim et al., 2009 and 2010, Wechter et al., 
2010). The main points could be summarized as follows: 
Hypertension, metabolic syndrome, renal failure and other risk factor for CVD. There is now 
sufficient evidence to strongly support a claim that increased SUA is an important 
etiological factor in at least one form of hypertension – early-onset primary hypertension. 
The sequence of events includes chronic hyperuricemia in mothers that may be transferred 
to the fetus and result in intrauterine growth retardation and a reduced number of 
nephrons. The reduced number of nephrons (and renal function), together with 
environmental and genetic factors, contributes to permanent hyperuricemia that reduces 
intra-renal NO release, activates the renin-angiotensin system, promotes vascular 
inflammation and inhibits endothelial cell proliferation, thus leading to a vasoreactive 
hypertension in the first step, and eventually to a salt-sensitive hypertension (Figure 2). 
 
Fig. 2. Development of uric acid-induced hypertension (re-drawn and modified after Feig et 
al., 2008). 
Otherwise, increased SUA has been repeatedly shown associated with hypertension and 
prehypertension. Moreover, in a number of prospective epidemiological studies in 
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normotensive subjects, increased SUA has repeatedly consistently predicted development of 
hypertension independently of other risk factors. The adjusted relative risk depended on the 
observational period, as well as on qualification of “increased SUA”. As reviewed by Feig et 
al. (Feig et al., 2008), in 6 studies with a total of 17 629 adult subjects, adjusted relative risks 
of development of hypertension (over 6-21 years) varied between 1.25 and 2.10 for “high vs. 
low” quartile or quintile of SUA, or for SUA levels >416 or >387 mol/L in men (vs. lower) 
and >357 mol/L in women (vs. lower) (all these cut-off points are lower than the 
conventional limits of hyperuricemia, see above). In the other 8 studies with a total of 25 500 
adult subjects, adjusted relative risks of hypertension (over 4 to 12 years) varied between 
1.10 and 1.65 for increase in SUA by one standard deviation or by 60 mol/L. Increased 
SUA has been repeatedly found in patients with metabolic syndrome, obese subjects, 
patients with dyslipidemia or glucose intolerance. In animal models, UA may induce a 
correlate of human metabolic syndrome. In a sample of a general population in Japan, 
irrespectively of gender, SUA levels >416 mol/L in men and >357 mol/L in women were 
found to cluster with hypertension, obesity, hypercholesterolemia, hypo-HDL 
hypercholesterolemia and hypertriglyceridemia (Nagahama et al., 2004). 
Stroke. A recent analysis of 16 prospective cohort studies that embraced 238 500 subjects and 
assessed predictivity of hyperuricemia (different definitions, but generally >380-416 mol/L 
irrespective of gender; or >416 mol/L in men and >360 mol/L in women) for 
development of stroke, indicated that in 10/10 studies which reported on stroke incidence, 
adjusted relative risks (RR) were >1.0. At the same time, adjusted relative risks of stroke-
related mortality were >1.0 in 10/11 studies that reported this outcome. The meta-analysis 
of adjusted RRs (random-effects with practically no heterogeniety) indicated RR of stroke: 
1.91 (95% CI 1.06-2.75) in a mixed population; 1.42 (0.94-1.90) in men, 1.42 (1.03-1.80) in 
women and 1.47 (1.19-1.76) overall (Kim et al., 2009). Relative risks of stroke-related death 
were: 1.61 (95% CI 1.13-2.09) in a mixed population; 1.20 (1.05-1.35) in men, 1.35 (1.04-1.66) 
in women and 1.26 (1.12-1.39) overall (Kim et al., 2009). 
Chronic heart failure (CHF). Chronic heart failure (CHF) is a typical setting in which the 
dilemma about UA as a “cause” or a (mere) “marker” is particularly actual (Duan & Ling, 
2008, Doehner et al., 2008, Bergamini et al., 2009). Numerous animal models have clearly 
confirmed the role of reactive oxygen species (ROS) in pathophysiology of the heart failure – 
there is a clear correlation between increased markers of oxidative stress within the heart 
and systemically, poorer survival and a number of functional measures of cardiac functions 
and hemodynamic consequences. The mechanisms of direct deleterious effects of ROS 
within the heart include alterations of calcium metabolism and propagation of endothelial 
dysfunction, inflammation and cellular responses resulting in remodeling, and they sum-up 
with their effects on the kidneys and systemic vasculature. The sources of cardiac ROS are 
multiple, but there is clear evidence, including humans, of increased cardiac XO activity. It 
inevitably results in enhanced production of UA, besides the generation of reactive oxygen 
and nitrogen species. Hence, it seems practically impossible to “separate” the effects of UA 
per se from those of activated XO. Be it as it may, increased SUA in CHF patients is 
associated with worse functional tests and, clearly, with a worse long-term survival. An 
analysis in CHF patients showed doubling and tripling of the adjusted relative risk of death 
(over time) (i.e., “independent effect of SUA”) for each 200 mol/L increase of SUA above 
the cut-off point of 400 mol/L. Moreover, the death risk was particularly increased when 
www.intechopen.com
Do We Need Another Look at Serum Uric Acid in Cardiovascular Disease? 
Serum Uric Acid as a Predictor of Outcomes in Acute Myocardial Infarction 
 
129 
SUA >565 mol/L was combined with a score of 2 or 3 based on the heart failure survival 
scoring system (Anker et al., 2003). Similarly, a study in acute HF patients demonstrated an 
increased risk of death in patients with SUA >458 mol/L as compared to those with SUA 
<416 mol/L (adjusted RR=1.45, 95% CI 1.03-2.05) and increase in RR by around 8% (CI 1-
15%) for each 60 mol/L increase in SUA (Alimonda et al., 2009). As reviewed by Pacher et 
al. (2006) and Bergamini et al. (2009), several randomized trials indicated improvements in 
cardiac and hemodynamic parameters in CHF patients treated with allopurinol (an XO 
inhibitor), even with indications of improved survival, but not all trials have been “positive” 
and uricosuric agents seemingly were not effective. 
Coronary heart disease (CAD). The link between SUA and CAD is two-fold. First, regardless of 
the actual mechanism (etiological factor vs. marker), increased SUA is clearly related to a 
number of CAD risk factors (hypertension, renal function, obesity, dyslipidemia, metabolic 
syndrome) and seemingly does independently predict CAD (regardless of whether a 
“direct” effect or “mediated” through other risk factors). A recent review and meta-analysis 
embraced 26 prospective cohort studies with 403 000 participants that reported on 
predictivity of SUA for occurrence of CAD and/or CAD-related mortality (Kim et al., 2010). 
The effect of SUA was expressed through a contrast of “hyperuricemia” vs “no 
hyperuricemia” (very different definitions in different studies; cut-offs for men ranged from 
321 mol/L to 458 mol/L; for women they ranged from 280 mol/L to 393 mol/L; and 
for mixed population from 387 mol/L to 416 mol/L) or as the effect of increase in SUA by 
60 mol/L. Based on 9 studies that reported adjusted risks of CAD incidence (adjusted for 
known CAD risk factors), pooled RRs for CAD incidence for “hyperucemia” vs. “no 
hyperuricemia” were: 1.04 (95% CI 0.90-1.17) in men; 1.07 (0.82-1.32) in women; 1.32 (0.57-
2.07) in mixed populations and 1.09 (1.03-1.16) overall (all random-effects estimates with 
very low-to-mild heterogeneity). Based on 9 studies that reported adjusted risks of CAD-
related mortality (adjusted for known risk factors), pooled RRs for CAD-related mortality 
for “hyperucemia” vs. “no hyperuricemia” were: 1.09 (95% CI 0.98-1.19) in men; 1.67 (1.30-
2.04) in women; and 1.16 (1.01-1.30) overall (all random-effects estimates with very low-to-
mild heterogeneity). Based on 4 studies that reported adjusted risks of CAD-related 
mortality based on increase in SUA by 60 mol/L, pooled RRs were: 1.10 (95% CI 0.96-1.24) 
in men; 1.17 (0.97-1.38) in women; 1.10 (1.06-1.14) in mixed population and 1.12 (1.05-1.19) 
overall (random-effects, low heterogeniety). Second, in animal models as well as in humans, 
cardiac ischemia-reperfusion injury involves increased ROS generation. The sources of ROS 
are, likely, multiple (as in the failing heart), but it is hypothesized that activation of XO 
contributes. The proposed mechanism is summarized in Figure 3: ischemia favors both 
intracellular accumulation of hypoxanthine and free calcium; the latter activates proteases 
that convert xanthine dehydrogenase to xanthine oxidase with a consequent generation of 
superoxide anion and UA. Several randomized trials, but not all, have shown that in 
patients undergoing elective coronary by-pass surgery allopurinol may reduce arrhythmias, 
improve cardiac index and cardiac output and reduce mortality (Wechter et al., 2010). 
In contrast to the broad attention that it has received in relation to the mentioned 
cardiovascular disease, until the recent years SUA has practically not been investigated in 
the setting of the outcomes of the acute myocardial infarction (AMI) or acute coronary 
syndromes in general. Several studies addressing this issue have been published since 2005 
and they are the main objective of this chapter. As in other SUA-CVD settings, the topic 
deserves some attention: an easily and reproducibly available marker with a consistent 
www.intechopen.com
Coronary Artery Disease 




Fig. 3. Proposed effects of ischemia-reperfusion for intracardiac activation of xanthine 
oxidase (XO) and generation of superoxide anion (O2-) and uric acid (re-drawn and 
modified after Pacher et al. 2006). 
predictive value may well improve risk stratification in AMI patients (and reflect on clinical 
decisions); considering the mechanisms relating SUA to ischemia-reperfusion (Figure 3) and 
other relevant intra- and extra-cardiac factors, it seems that, should a SUA-AMI outcome 
relationship be established, there would be a sound rationale for implementation of an 
intervention based on XO inhibition, regardless of whether SUA is primarily an effector or a 
“mere marker”. 
2. Do serum uric acid levels predict outcomes in acute myocardial infarction 
patients? 
2.1 Chronology and a general description of the relevant studies 
Study essentials are summarized in Table 2. 
In 2005, Kojima and colleagues (Kojima et al., 2005) published the results of the Japanese 
Acute Coronary Syndrome Study (JACSS) – a retrospective analysis of a database on acute 
coronary syndrome patients generated as a result of collaboration of 35 institutions in Japan 
during 2002 (January – December). Patients (N=1124) were defined as consecutive AMI 
patients admitted to a hospital within 48 hours since the symptom onset (with SUA 
determined on admission). No distribution of patients by AMI type was given – whether 
with (STEMI) or without (NSTEMI) ST elevation. However, 943 (84%) patients underwent 
immediate reperfusion [predominantly by a percutaneous coronary intervention (PCI) and 
only sporadically by pharmacological thrombolysis] (Table 2) and could be considered as 
STEMI patients, whereas the remaining 181 could be considered as NSTEMI patients. Men 
prevailed (70%) and the mean age was 68 years. Higher on-admission SUA values were 
independently associated with the male sex, higher body mass index (BMI), higher serum 
creatinine, higher Killip’s class and a history of hypertension and a previous AMI. Patients 
were classified based on the on-admission SUA quartiles and the analysis focused on a 
comparison of the outcomes between patients within the 4th quartile [(n= 276, SUA >399 
mol/L, which is higher than the cut-off value for hyperuricemia in women, and is just 
below the cut-off value of hyperuricemia in men (420 mol/L)] and those within the 1st 
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quartile [n=273, SUA <274 mol/L, which is within the range of “low-normal SUA” in men, 
and just above the cut-off value of “low-normal SUA” in women (250 mol/L)]. The 
primary outcome of interest was all-cause mortality (survival) during the observational 
period, which averaged 450 days and the maximum length was 700 days. The death-rate 
was higher among the 4th quartile patients (12% vs. 3%) and 4th quartile SUA values were 
found independently predictive of all-cause mortality: in a Cox proportional hazard 
regression model with adjustment for the Killip’s class, age and peak creatine 
phosphokinase (CPK) value (selected through a stepwise procedure among a number of 
others, p<0.05), HR was 3.72 (95% CI 1.42-9.74). The analysis that considered SUA as a 
continuous variable indicated an adjusted death risk increase of around 22% by each 
increase in SUA by 50 mol/L (HR= 1.22, 95% CI 1.11-1.35). No increase in the risk of death 
was found in patients within the 2nd (n=299, SUA 274-333 mol/L) or the 3rd (n= 276, SUA 
333-399 mol/L) quartile. 
In 2007, Valente and colleagues (Valente et al., 2007) reported the results of a prospective 
study conducted at a single PCI-performing center in Italy. The report focused on STEMI 
patients presenting with a cardiogenic shock and undergoing acute PCI, i.e., within 6 hours 
since the symptom onset (between January 2004 and June 2005) (N=45). Patients were 
classified as those who died during the in-hospital stay (“cases”, n=20, 13 men, mean age 78 
years) and those who survived (n=25, 19 men, mean age 66 years). Serum uric values taken 
on admission to intensive coronary care unit (ICCU) were higher in “cases” than in 
“survivors”: (meanSD) 434137 mol/L vs. 351137 mol/L (p=0.040). In a univariate test, 
on-admission SUA >387 mol/L (vs. below) (which qualifies as hyperuricemia in women, 
but not entirely in men) was associated with higher odds of in-hospital death: OR= 6.7 (95% 
CI 1.4-31.8), but this association did not hold in a multivariate model (adjusted OR not 
reported). 
The same group (Lazzeri et al., 2010) extended their study report by including all 
consecutive STEMI patients who underwent acute PCI (within 12 hours since the symptom 
onset), regardless of the clinical presentation (N=466). Patients were classified as those with 
on-admission (to ICCU) SUA >387 mol/L (“high”, n=100, 78.5% men, average age 72 
years) and those with SUA 387 mol/L (“normal”, n=366, 78.6% men, average age 64 
years). In-hospital mortality, the primary outcome, was higher in “high” SUA patients (9.0% 
vs. 2.5%). “High” on-admission SUA was found independently predictive of higher in-
hospital mortality: in a logistic regression model with adjustment for age, left ventricular 
ejection fraction (LVEF), fibrinogen and peak troponin I levels (selected through a backward 
procedure among a number of others, p<0.05), OR was 1.82 (95% CI 1.15-2.86). With further 
adjustments for sex, Killip’s class and diuretic use, OR=2.02 (95% CI 1.47-2.78). 
In 2009, Car and Trkulja (Car&Trkulja, 2009) reported a retrospective analysis of 
consecutive AMI patients [N=621, 481 STEMI (77.5%), 140 NSTEMI; 64.7% men, average 
age 65 years) treated exclusively conservatively (between 1996 and 2001), with a low rate 
of fibrinolytic reperfusion (10% of STEMI patients), at a single center in Croatia, all 
admitted within 48 hours since the symptom onset. Outcomes of primary interest were in-
hospital mortality, 30-day mortality and, for those who survived the first 30 days post-
index event (considering that mortality after AMI is higher within the first 30 days than in 
any other subsequent 30-day period), long-term all-cause mortality (n=544; follow-up 
extended to up to 13 years). 
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In-hospital mortality was 10% and 30-day mortality was 12.4%. Higher on-admission SUA 
was independently predictive for both outcomes: in modified Poisson regression models (to 
yield relative risk, rather than odds ratio), with adjustment for age; sex; history of stroke, 
hypertension, AMI and HF; peak creatine phosphokinase (CPK), right bundle branch block 
(RBBB), serum creatinine (selected through a backward procedure, p<0.1) and AMI type 
(forced), RR for each increase in SUA by 50 mol/L was 1.08 (95% CI 1.01-1.16) for in-
hospital mortality, and it was 1.08 (95% CI 1.02-1.15) for 30-day mortality. Among those who 
survived the first 30-day post-index event, mortality during the subsequent period (up to 13 
years) was 32.2%. Higher on-admission SUA was independently predictive of poorer long-
term survival: in a Cox proportional hazard regression model, with adjustment for age, 
serum creatinine, heart failure at discharge, use of digitalis and SUA*age interaction 
(selected through a stepwise procedure among a number of others, p<0.1), HR for each 
increase in SUA by 50 mol/L was 1.65 (95% CI 1.10-2.44). 
In 2010, Rentoukas and colleagues (Rentoukas et al., 2010) reported on a small, single-center 
randomized controlled trial in Greece in which consecutive acute STEMI patients (June 2005 
– June 2006) undergoing PCI within 3-12 hours post-symptom onset were randomized to 
receive allopurinol (n=21, 15 men, mean age 65 years) or placebo (n=19, 14 men, mean age 
64 years) for 30 days. A loading dose of allopurinol (400 mg) was administered as soon as 
AMI was diagnosed, and treatment continued with 100 mg/day. During the observed 30 
days, allopurinol-treated patients had lower peak CPK, peak CK-MB and lower peak 
troponin I levels, and a higher proportion of patients experienced a complete ST-elevation 
resolution (all p<0.05). 
In 2010, Kowalczyk and colleagues (Kowalczyk et al., 2010) published a retrospective 
analysis of consecutive STEMI patients undergoing PCI at a single center in Poland 
(between 2000 and 2007). Timing of PCI relative to the symptom onset was not specified. 
Patients were selected as those having “impaired renal function”: either having a “baseline 
kidney dysfunction” (BKD) defined as estimated glomerular filtration rate (eGFR) <60 
mL/min71.73m2 based on serum creatinine taken on admission or within 12 hours since 
admission, or having a “contrast-induced nephropathy” (CIN) defined as an increase in 
serum creatinine >44.2 mol/L or >25% from the baseline value, within 48 hours since PCI. 
A total of 1015 such patients were included. They were classified as those with 
hyperuricemia (SUA >420 mol/L determined at the same time as serum creatinine; which 
is in line with the definition of hyperuricemia in men, and is above the cut-off value of 
hyperuricemia in women) (n= 352, men 64.2%, mean age 67 years) and those without it (n= 
663, men 59.6%, mean age 64 years). The observational period extended to up to 7 years 
post-PCI (average 3 years). Besides being older and with a higher prevalence of men, 
hyperuricemic patients were more frequently diabetic, had previous PCI, hypertension, 
eGFR <60 mL/min/1.73 m2 and had lower LVEF at discharge. In-hospital, 30-day, 1-year 
and entire-period all-cause mortalities were higher in hyperuricemic vs. non-hyperuricemic 
patients (Table 2). The main analysis was that of all-cause mortality over the entire observed 
period (case-fatality rate 32.7% for hyperuricemia vs. 18.6% for no hyperuricemia). 
Hyperuricemia independently predicted mortality: in a Cox proportional hazard regression 
model with adjustment for age, cardiogenic shock on admission, diabetes, eGFR <60 
mL/min/1.73 m2, LVEF at discharge, incomplete revascularization and lack of TIMI flow 
grade 3 after PCI of the infarct-related artery (selected among a number of other covariates 
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in a stepwise procedure, p<0.05), adjusted HR=1.17 (95% CI 1.05-1.29). In the same model 
but considering SUA as a continuous variable, HR (by 50 mol/L increase in SUA)= 1.04 
(95% CI 1.02-1.06). 
The patients were further analyzed separately as BKD (n=503; with hyperuricemia n=225, 
without it n=278) and as CIN patients (n= 693, with hyperuricemia n=243, without it n=450) 
(these two subgroups partly overlapped – some patients with BKD later-on developed CIN). 
Crude mortality rates for BKD and CIN patients are summarized in Table 2. High SUA 
independently predicted mortality in both subgroups. BKD: adjusted HR for hyperuricemia 
= 1.38 (95% CI 1.23-1.53), adjusted HR by 50 mol/L SUA increase = 1.05 (95% CI 1.03-1.07); 
CIN: adjusted HR for hyperuricemia = 1.21 (95% CI 1.05-1.37), adjusted HR by 50 mol/L 
SUA increase = 1.06 (95% CI 1.04-1.09). 
In 2011, Basar and colleagues (Basar et al., 2011) reported on their prospective observational 
study in 185 consecutive STEMI patients undergoing PCI within 12 hours since the 
symptom onset (N=185) (time-period not reported, most author affiliations in Turkey). 
Patients were classified as those having on-admission SUA >387 mol/L (“high”; above the 
cut-off of hyperuricemia in women, but below it in men) (n= 45, 80% men, mean age 60 
years) and those with on admission SUA below this level (“normal”, n= 140, 80% men, mean 
age 58 years). Patients with “high” SUA more frequently had a history of hypertension, 
prior AMI, multivessel disease and had higher Killip’s class at presentation. They were 
followed-up for 1 year. In-hospital mortality was higher in patients with “high” SUA (6.6% 
vs. 2.8%). The main outcomes of interest were all-cause mortality within 1-year period and 
proportion of patients with abnormal myocardial perfusion at 1 year post-PCI based on 
TIMI myocardial perfusion grade. “High” SUA independently predicted both outcomes. In 
a logistic regression model with adjustment for TIMI risk score, abnormal TIMI perfusion 
grade at discharge, LVEF at discharge, multivessel disease (selected among a number of 
covariates in a stepwise procedure, p<0.1), time to reperfusion and serum creatinine (forced 
covariates), OR for death was 1.29 (95% 1.14-2.08). When SUA was considered as a 
continuous variable (with the same adjustments), OR by 50 mol/L increase in SUA was 
1.10 (95% CI 1.02-1.14). Considering the proportion of patients with abnormal myocardial 
perfusion, adjusted OR (Killip class, multivessel disase, corrected TIMI time-frame count, 
selected based on p<0.05) was 2.14 (95% CI 1.17-4.19). 
In 2011, Bae and colleagues (Bae et al., 2011) published a retrospective analysis of a 
multicenter AMI registry in South Korea. Embraced were 850 consecutive AMI patients 
(during 2006 and 2007), 391 (46%) of whom were depicted as STEMI patients. The remaining 
patients were likely NSTEMI, since typical clinical AMI presentation with an increase in 
cardiac enzymes was prerequisite for inclusion. Overall, 623 (73.3%) patients underwent PCI. 
Other reperfusion procedures were not specified. Also, time elapsed between the symptom 
onset and admission and timing of SUA measurement were not specified. SUA values were 
collected retrospectively since they had not been originally entered into the registry. Patients 
were classified as those who, during a 6-month period, experienced a composite outcome of 
death or non-fatal reinfarction or revascularization (MACE) (n=109) and those who did not 
(n=741). They were also classified as those with on-admission SUA >420 mol/L (cut-off for 
hyperuricemia in men, and higher than that in women) (n= 172, 74.4% men, mean age 66.5 
years) and those with lower SUA levels (n= 678, 67.2% men, mean age 67 years). Besides the 
fact that they were more frequently men and somewhat older, hyperuricemic patients more 
www.intechopen.com
Coronary Artery Disease 













AMI, type not 
specified; 
admission 48 
hrs since onset; 
N= 1124 
Reperfusion= 943 












up maximum 700 
days 
4th vs. 1st quartile SUA 
30-day MACE. 14% vs. 5%; 
OR=2.83, p=0.001 
30-day cardiac death. 11% vs. 
2%; OR=6.54, p<0.001 
30-day all death. 11% vs. 2%, 
OR= 5.63, p<0.001 
All-cause mortality long-term. 
12% vs. 3%, HR= 3.75, 
p<0.001 
SUA by 50 mol/L 
All-cause mortality long-term. 
HR= 1.28, p<0.001 
4th vs. 1st quartile SUA 
All-cause mortality long-
term.  
HR=3.72 (95% CI 1.42-
9.74) 
SUA by 50 mol/L 
All-cause mortality long-
term. 
HR= 1.22 (95%CI 1.11-
1.33) 
 
Ajdust: Killip’s class, peak 








STEMI with CS, 
undergoing PCI 




SUA >387 mol/L (vs. 










going PCI within 




SUA >387 mol/L (vs. 
below) – 9.0% vs. 2.5%, 
OR=3.9, p=0.006 
SUA >387 mol/L (vs. 
below) 
OR= 1.82 (95%CI 1.15-
2.86)/Adjust: age, LVEF, 
fibrinogen, peak Tn I 
(p<0.05) 
OR=2.02 (95%CI 1.47-2.78) 
/ further: sex, COPD, 










48 hrs since 














up up to 13 
years; n=544 who 
survived first 30 
days 
In-hospital mortality
SUA 50 mol/L: RR=1.20, 
p<0.05 
30-day mortality 
SUA 50 mol/L: RR=1.19, 
p<0.05 
All-cause mortality long-term 
SUA 50 mol/L: HR=1.14, 
p<0.05 
In-hospital mortality 
SUA 50 mol/L: RR=1.08 
(95%CI 1.01-1.16)  
30-day mortality 
SUA 50 mol/L: RR=1.08 
(95%CI 1.02-1.15)  
Ajdust: age; sex; AMI 
type; prior CVI, 
hypertension, AMI, HF; 




SUA 50 mol/L: HR=1.65 
(95%CI 1.13-2.18) 
Adjust: creatinine, age, 











going PCI 3-12 
hrs since onset. 




peak CPK, peak 
CK-MB, peak Tn 
I, resolution of ST 
elevation 
Allopurinol: lower peak 
CPK, MB-CPK and Tn I, 
greater proportion of “full 




Do We Need Another Look at Serum Uric Acid in Cardiovascular Disease? 














going PCI (time 





























SUA >420 mol/L (vs. 
below) 
In-hospital mortality 
All: 14.5% vs. 7.1%, p<0.001 
BKD: 18.2 vs. 12.2%, p=0.060
CIN: 19.0% vs. 6.4%, p<0.001
30-day mortality 
All: 16.9% vs. 7.7%, p<0.001 
BKD: 19.6% vs. 12.9%, 
p=0.04 
CIN: 19.8% vs. 6.9%, p<0.001
1-year mortality 
All: 25.0% vs. 13.7%, p<0.001
BKD: 31.5% vs. 18.3%, 
p<0.001 
CIN: 28.0% vs. 13.1%, 
p<0.001 
>1 year mortality 
All: 32.7% vs. 18.6%, p<0.001
BKD: 41.3% vs. 25.9%, 
p<0.001 
CIN: 35.4% vs. 16.7%, 
p<0.001 
SUA >420 mol/L (vs. 
below) 
Overall observed period 
All: HR= 1.17 (95% CI 
1.05-1.29) 
BKD: HR= 1.38 (95% CI 
1.23-1.53) 
CIN: HR= 1.21 (95% CI 
1.05-1.37) 
SUA by 50 mol/L 
Overall observed period 
All: HR= 1.04 (95% CI 
1.02-1.06) 
BKD: HR= 1.05 (95% CI 
1.03-1.07) 
CIN: HR= 1.06 (95% CI 
1.04-1.09) 
Adjust: All - age, CS on 
admission, DM, LVEF at 
discharge, incomplete 
revascu-larization, lack of 
TIMI flow grade 3 after 
PCI of the infarct-related 
artery, BKD 
BKD – age, CS on 
admission. LVEF at 
discharge, incomplete 
revascularization, lack of 
TIMI flow grade 3 after PCI 
of the infarct-related artery 
CIN: age, CS on 
admission, LVEF at 
discharge, incomplete 
revascularization, BKD/ 








going PCI within 









SUA >387 mol/L (vs. 
below) 
In-hospital mortality 
6.6% vs. 2.8%, p<0.01 
1-year all-cause mortality 




1-year impaired perfusion 
correlation r=0.46, p<0.001 
SUA >387 mol/L (vs. 
below) 
1-year all-cause mortality 
OR= 1.29 (95%CI 1.14-
2.08)/Adjust: TIMI risk 
score, abnormal TIMI 
perfusion grade at 
discharge, LVEF at 
discharge, multi-vessel 
disease (p<0.1) + time to 
reperfu-sion, serum 
creatinine 
1-year impaired perfusion 
OR= 2.14 (95% CI 1.17-
4.19)/Adjust: Killip 
multives. disease, TIMI 
time-frame count 
SUA by 50 mol/L 
1-year all-cause mortality 
OR=1.10 (95% CI 1.02-
1.14) /Adjust: same 
www.intechopen.com
Coronary Artery Disease 




























MACE: death or 
non-fatal AMI or 
revascularization 
SUA >420 mol/L (vs. 
below) 




Patients with MACE (n=109) 
had higher SUA than those 
without MACE (n= 741), 
p<0.001 
SUA 50 mol/L 
HR: 1.24 (95% CI 1.06-1.46) 
/Adjust: age, BMI, systolic 
blood pressure, heart rate, 
diabetes, hyperlipidemia, 
previous AMI, Killip class, 
PCI, WBC, hemoglobin, 
sodium, potassium, eGFR, 












310 (24.9%) acute 












SUA >416 (M) or >387 (F) 
mol/L 
OR= 5.48 (95% CI 3.06-9.84) 
 
SUA >416 (M) or >387 (F) 
mol/L 
OR= 4.74 (95% CI 1.96-
11.4) /Adjust: contrast 
amount, diabetes, 
hemoglobin, PCI post-
AMI, eGFR <60 
mL/min/1.73m2 
SUA – serum uric acid; OR – odds ratio; RR – relative risk; HR – hazard ratio (relative risk); M – male, F 
– female, BKD – baseline kindey dysfunction; CIN – contrast-induced nephropathy; COPD – chronic 
obstructive pulmonary disease; CPK – creatine phosphokinase; CPK-MB – creatine phospnokinase 
myocardial band; CS – cardogenic shock; CVI – cerebrovascular insult; DM – diabetes mellitus; eGFR – 
estimated glomerular filtration rate; HF – heart failure; hs-CRP – highly specific c-reactive protein; 
LVEF – left ventricular ejection fraction; MACE – major adverse cardiac events, NSTEMI – non-ST-
elevation myocardial infarction; NT-ProBNP – N-termina-pro-B type natriuretic peptide; PCI – 
percutaneous coronary intervention; RBBB – right bundle branch block; RCT – randomized controlled 
trial; STEMI – ST-elevation myocardial infarction 
Table 2. Summary of the studies of prognostic value of serum uric acid levels (SUA) in 
patients with acute myocardial infarction (AMI). Data are listed as presented in orginal 
publications. However, odds ratios and relative risks associated with SUA as a continuous 
variables were all re-calculated to 50 mol/L increase to enable comparability of results. 
frequently presented with a higher Killip class, more frequently had a history of 
hypertension and coronary artery disease, less frequently underwent PCI, had lower 
hemoglobin and serum sodium, lower eGFR, lower LVEF, and had higher potassium, high-
sensitivity CRP and higher levels of pro-B-type natriuretic peptide (NT-ProBNP). Patients 
experiencing MACE had higher SUA levels and patients with hyperuricemia more 
frequently experienced MACE (24.4% vs. 9.9%, p<0.001). Higher on-admission SUA 
independently predicted 6-month occurrence of MACE: in a proportional hazard regression 
model with adjustment for age, BMI, systolic blood pressure, heart rate, diabetes, 
hyperlipidemia, previous AMI, Killip class, PCI, WBC, hemoglobin, sodium, potassium, 
eGFR, NT-ProBNP, hs-CRP (all showing univariate associations with the outcome, but not 
all were independently associated with the outcome), HR for MACE by 50 mol/L increase 
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in SUA was 1.24 (95% CI 1.06-1.46). They also noticed that SUA and NT-ProBNP additively 
improved the predictivity of the entire model (as judged on global chi-square increase): 
adding SUA or NT-ProBNP to conventional risk factors comparably increased the global 
chi-square, whereas adding both, yielded a model with the highest chi-square.  
Park and colleagues (Part et al. 2011) recently reported a retrospective analysis of 1147 
consecutive patients from a single center in South Korea (between mid 2006 and end of 
2009) who underwent PCI. However, only 310 (24.9%) were STEMI patients undergoing 
acute PCI, whereas the rest underwent elective procedures. The report is interesting because 
it showed that SUA >416 mol/L in men and >387 mol/L (in line with “conventional” 
definition of hyperuricemia) independently predicted development of acute kidney injury 
(AKI) (increase in serum creatinine > 44 mol/L or >50% over baseline) within 7 days from 
PCI. Hyperuricemia was particularly predictive of AKI when combined with eGFR before 
PCI <60 mL/min/1.73 m2. Also, in univariate tests, AKI strongly predicted in-hospital 
mortality (19.6% vs. 0.8%, OR= 28.9 (95% CI 11.4-73.3), as did hyperuricemia – OR= 3.01 
(95% CI 1.19-7.87). 
From the viewpoint of predictive value of SUA for AMI outcomes, 7 out 9 of the described 
studies are of primary interest. The small RCT of allopurinol in STEMI patients undergoing 
PCI is interesting in that indicates the potential of an intervention affecting the XO-SUA 
system in this setting (Rentoukas et al., 2010). The study from South Korea (Park et al., 2011) 
reporting on consecutive PCI patients (predominantly elective, but 25% also acute) is of 
interest as it indicates a possible element of mechanism(s) by which increased SUA, or a 
condition characterized by increased SUA (specifically, hyperuricemia), might influence 
AMI outcomes in subjects undergoing acute PCI (potential effects on the renal function). 
Most of the seven studies of primary interest were retrospective (Table 2), which, per se, could 
be viewed as a methodological drawback. However, considering the particulars of AMI and 
AMI treatment (an acute condition, typically handled after a standardized procedure with a 
detailed prospective monitoring and data recording), a retrospective data analysis is less likely 
to be biased in this setting than in some other situations. Clearly, however, susceptibility to 
some sources of bias remains (e.g., patient selection, physician’s skill, accuracy in data 
recording, pattern of missing data etc.). The fact that data come from different parts of the 
world (Japan, Korea, various European and Middle-East countries) and different settings 
(STEMI, NSTEMI, mixed, PCI, thrombolysis or no reperfusion) should be viewed as a 
possibility to evaluate whether predictivity of SUA in this setting is robust and holds across 
genetic and cultural (e.g., nutrition, alcohol consumption, smoking habits) differences that 
might influence SUA levels and across different AMI types and treatment modalities.  
2.2 Prediction of short-term outcomes 
When considering predictivity of “on-admission” SUA levels (that is, taken at hospital 
admission, before any major intervention, as a part of a diagnostic work-up), one question is 
inevitable: what do the “on-admission” SUA levels reflect? A pre-existing condition? An 
acutely developed condition induced by AMI? Or, both?. Indeed, AMI per se causes a 
reduction in renal function (thus potentially reflecting on SUA levels due to a reduced 
excretion – studies on kinetics of creatinine elimination suggest that changes due to a 
sudden decline in renal function are to be expected within 5-6 hours (Hallynck et al., 1981, 
Hillege et al., 2003). Furthermore, as depicted in Figure 3, cardiac ischemia is likely to result 
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in activation of XO. However, a reduction in glomerular filtration seen after AMI has been 
estimated at 1-3 mL/min for the period between AMI onset and day 3 post-AMI (Hillege et 
al., 2003), and by analogy to a failing heart (Doehner et al., 2008), increased cardiac XO 
activity apparently also needs certain time to occur. Therefore, it is likely that “on-
admission” SUA values, when taken, for example, within first 48 hours since AMI onset are 
likely to largely represent the pre-existing condition. From the viewpoint of predictive 
power of UA, these observations are not crucial, because the question is simple: does this 
marker, taken at this very moment (regardless of what it represents), predict future events? 
They are, however, of interest when considering the possible “mechanistic” contribution of 
SUA to events that are to occur in a short subsequent period of time (e.g., in-hospital 
mortality or 30-day mortality) – clearly, the molecular/cellular mechanisms of SUA (or XO, 
for that matter) elaborated earlier also need to act for a certain period of time for their 
detrimental effects to become obvious.  
In the subsequent text, word “effect” will be used to describe the relationship between SUA 
(as a potential predictor) and the outcomes. It does not imply causal relationship between 
the two, but is used simply because it is inherent to regression analysis on which all of the 
studies were based. Furthermore, the focus will be on adjusted estimates (ORs, RRs), i.e., 
those obtained in individual studies by accounting for relevant confounders. Where 
applicable, pooled estimates based on adjusted individual results were generated by 
conventional meta-analytical methodology for summary results. Since most of the studies 
reported on event rates >10% and used odds ratios, whereas some reported relative risks, 
adjusted odds ratios were corrected and transferred into relative risks as described by 
Zhang and Yu (Zhang&Yu, 1998) in order to allow for pooling of data. 
2.2.1 Overall effect of “high” SUA (hyperuriceima) 
As depicted in Table 2, in all studies that reported on short-term outcomes, i.e., in-hospital 
mortality and 30-day mortality, higher on-admission SUA, depicted as values above some 
cut-off (and regardless of this value) or treated as a continuous variable – consistently was 
associated with higher mortality: in STEMI patients treated with PCI, in STEMI PCI-treated 
patients with impaired renal function (as a pre-existing condition or contrast-induced), in a 
mixed population of NSTEMI and STEMI patients with poor reperfusion treatment). Hence, 
it appears safe to say that, regarding short-term outcomes, increased SUA (regardless of 
how defined) is a “robust” predictor that does not appear conditional on type of AMI 
and/or treatment modality. Table 3 summarizes the pooled estimate of unadjusted relative 
risk of in-hospital mortality for “high” SUA (based on studies in Table 2). Practically 
without inconsistency, the pooled estimate indicates around 2.57 times higher (unadjusted) 
risk of in-hospital mortality associated with “high” SUA. 
Only 2 studies reported adjusted estimates of risk associated with “high SUA” in respect to 
in-hospital mortality, Lazzeri et al., 2010 as odds ratio, and Trkulja&Car 2009, using SUA as 
a continuous variables. Data from Lazzeri et al., 2010 were converted to adjusted relative 
risk – 1.97 (95% CI 1.45-2.66); and data from Car&Trkulja 2009 were used to calculate 
adjusted relative risk for “high” SUA – 1.82 (95%CI 1.13-2.93). The pooled estimate of these 
two adjusted RRs is 1.93 (95% CI 1.49-2.49). Hence, “high” SUA (defined here more or less 
consistently as SUA within the range of “hyperuricemia”) apparently independently 
predicts in-hospital mortality. 
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Pooled (random) (I2=0.5%, heterogenitey p=0.389) 2.57 (1.97-3.34) 
Table 3. Meta-analysis of unadjusted relative risk of in-hospital mortality associated with 
“high” SUA. Valente et al., 2007 was not considered separately, because reported patients 
were included also in Lazzeri et al., 2010. Data for Car&Trkulja 2009 were recalculated from 
original data (since not reported in the original publication). 
Table 4 summarizes the pooled estimate of unadjusted relative risk of “30-day mortality” for 
“high” SUA (based on studies in Table 2). With rather high inconsistency, the pooled 
estimate indicates around 2.82 times higher (unadjusted) risk of 30-day mortality associated 
with “high” SUA. 
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>420 M, >360 
F 
42/171 41/450 2.70 (1.82-3.97) 
Kowalczyk 
2010 
STEMI, PCI >420 51/352 47/663 2.07 (1.45-2.98 
Total   123/799 108/1961  
Pooled (random) (I2=65.3%, heterogenitey p=0.056) 2.82 (1.86-4.29) 
Table 4. Meta-analysis of unadjusted relative risk of 30-day all-cause mortality associated 
with “high” SUA. Data for Car&Trkulja 2009 were recalculated from original data (since not 
reported in the original publication). 
No study reported an adjusted risk of 30-day mortality for “high” SUA. Car&Trkulja 2009 
(Table 2) reported an adjusted RR considering SUA as a continuous variable. Original data 
were used to calculate RR for “high” SUA (>420 or >360 mol/L in men and women, 
respectively) with the same adjustments as depicted in Table 2 – RR= 1.50 (95% CI 1.05-2.40). 
Hence, it appears that “high” SUA (defined more or less consistently as “hyperuricemia”) 
independently predicts 30-day mortality after AMI. 
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2.2.2 Effect of high SUA in respect to gender and AMI type 
All studies reporting the effects of SUA on short-term outcomes of AMI (Table 2) included 
patients of both sexes, but men prevailed in all studies. Two of these studies (Kojima et al., 
2005, Car&Trkulja 2009) included both STEMI and NSTEMI patients, while remaining 
included exclusively acute PCI-treated STEMI patients (Table 2). Considering the overall 
effects of SUA (Table 3, Table 4), it seem reasonable to assume that the effects of SUA are 
consistent in both genders and both in STEMI and NSTEMI. For the purpose of this text, 
original data reported by Car&Trkulja 2009, apart from 8 patients who presented with 
cardiogenic shock (which troubles the interpretation of on-admission SUA) were analyzed 
for the effects of SUA on 30-day mortality by sex and type of AMI. SUA levels were 
considered as a continuous variable or a 3-level categorical variable: low-normal SUA values 
were defined as <310 µmol/l in men and <250 µmol/l in women; hyperuricemia was 
defined as SUA >420 µmol/l in men and >360 µmol/l in women; whereas high-normal SUA 
was defined as values between these limits. Figure 4 summarizes univariate effects of SUA 
on 30-day mortality. Mortality consistently increased across the range of SUA values, but 
the most prominent increase in mortality was observed at the cut-off of hyperuricemia, 
particularly in NSTEMI patients. 
Figure 5 summarizes univariate effects of SUA on 30-day mortality in sex-by-AMI-type 
subgroups. Mortality consistently increased across the range of SUA values, but the most 
prominent increase in mortality was seen at the cut-off of hyperuricemia. The particularly 
prominent increase in mortality of NSTEMI is apparent in both men and women. 
In multivariate analysis, a number of potential covariates were considered: pre-index event 
medical history, on-admission laboratory data (creatinine and eGFR [<60 mL/min/1.73 m2], 
triglycerides, total and HDL and LDL cholesterol, peak CPK-MB, serum fibrinogen, white 
blood cells, hemoglobin, CRP), electrocardiographic particulars, pre-index event treatment 
and treatments delivered between the index event and 30-day post symptom onset. 
Multivariate model-building details are given in caption to Figure 6 which summarizes 
univariate and multivariate effects of SUA, as a continuous variable or as a contrast of 
“hyperuricemia” vs. “normal SUA”, on 30-day mortality across gender, AMI type and 
gender-by-AMI-type subgroups. Data strongly suggest that high SUA (and specifically 
hyperuricemia) independently predicts 30-day mortality across all subgroups. The 
pronounced increase in mortality in hyperuricemic NSTEMI patients is maintained in 
multivariate analysis, as well. In practical terms, it may suggest that hyperuricemic NSTEMI 
patients might require a particularly closer monitoring. Of notion, however, the analyzed 
cohort was treated exclusively conservatively with very scarce use of thrombolytic 
reperfusion in STEMI patients. 
Considering limited subgroup size/number of deaths, models in gender-by-AMI type 
subgroups included only selected adjustments (stepwise, p<0.1 to enter, p<0.05 to stay). 
Adjustments in men-STEMI: prior AMI and post-index event treatments – antiplatelets, 
ACE inhibitors, class I/III antiarrhythmics. Adjustments in women-STEMI: right bundle 
branch block and post-index event treatments – antiplatelets, ACE inhibitors, diuretics and 
beta blockers. Adjustments in men-NSTEMI: age. Adjustments in women-NSTEMI: prior 
symptomatic chronic heart failure, post-index event antiplatelet use. 
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Fig. 4. Univariate effects of SUA on 30-day mortality by sex and AMI type. Estimate 
probability of dying across the range of SUA values (A, B) and proportion dying among 
low-normal, high-normal SUA and hyperuricemic patients (B, D) (based on the cohort 
described in Car&Trkulja 2009). Vertical lines in A and B denote the limits of hyperuricemia 
in men and women. 
2.2.3 Effect of high SUA in respect to renal function 
All studies reporting effects of SUA on short-term outcomes (Table 2) included a variable 
proportion of patients with reduced renal function (e.g., eGFR <60 mL/min/1.73 m2). The 
study by Kowalczyk and colleagues (Kowalczyk et al., 2010) specifically included only 
patients with an impaired renal function (eGFR <60 mL/min/1.73 m2 at baseline or 
contrast-induced renal injury). The consistency of the effects of SUA across trials suggests 
that, likely, effects of SUA hold in both patients with a reduced and those with a preserved 
renal function. No study reported specifically on patients with different levels of eGFR. For 
the purpose of this text, the cohort by Car&Trkulja (Car&Trkulja 2009) is re-analyzed 
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Fig. 5. Univariate effects of SUA on 30-day mortality in sex-by-AMI-type subgroups (based 
on the cohort described in Car&Trkulja 2009). Estimated probability of dying across the 
range of SUA values (A) and proportion dying among low-normal, high-normal SUA and 
hyperuricemic patients. Vertical lines in A denote limits of hyperuricemia in men and 
women. 
separately for patients with eGFR <60 mL/min/1.73 m2 and those with eGFR 60 
mL/min/1.73 m2. Levels of SUA values were defined as in the previous section. As 
shown in Figure 7, probability of 30-day mortality increased across the range of SUA 
values, and particularly at the level of hyperuricemia, in patients with eGFR <60 
mL/min/1.73 m2, but not in those with eGFR 60 mL/min/1.73 m2. Multivariate analysis 
(potential adjustments as described in the previous section) demonstrated an independent 
association between higher SUA and particularly hyperuricemia and 30-day mortality in 
patients with reduced, but not in those with a preserved renal function. Univarite and 
multivariate SUA effects are summarized in Table 5. Reduced renal function is a well-
established predictor of poor outcomes in AMI patients (specifically, eGFR <60 
mL/min/1.73 m2 has been repeatedly shown as a “break-point” of a marked increase in 
mortality). The present data suggest that increased SUA, i.e., hyperuricemia adds a 
considerable additional risk in patients with a reduced renal function. However, the 
current data should be viewed with a caution, since they refer exclusively to patients not 
treated with PCI. From a mechanistic standpoint, on the other hand, it seem plausible that 
detrimental effects of increased SUA are particularly obvious in patients with a reduced 
renal function (and not, or less so, in patients with a preserved renal function) – the 
potentially contributing molecular and cellular effects of SUA are more likely to manifest 
under the conditions of increased oxidative stress/reduce antioxidant capacity as it is 
seen in renal failure. 
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Fig. 6. Univariate and multivariate effects of SUA (as a continuous variable, by 50 mol/L 
increase, left; and as a contrast of hyperuricemia vs. normouricemia, right) on 30-day 
mortality in subgroups by gender and type of AMI (based on the cohort described in 
Car&Trkulja 2009). Effects are presented as unadjusted and adjusted odds ratios (OR) 
(horizontal lines are 95% confidence intervals) by 50 mol/l increase in SUA or for the 
contrast hyperuricemia vs normal SUA. Multivariate models in men, women, STEMI and 
NSTEMI included lag-time between symptom onset and admission and on-admission 
estimated glomerular filtration rate (<60 or 60 ml/min/1.73 m2) as default adjustments. 
Other adjustments were selected in a stepwise procedure (p<0.1 to enter and p<0.05 to stay). 
Selected adjustments in men: prior AMI, right bundle branch block, and post-index event 
treatments – antiplatelets, beta blockers, diuretics, class I/III antiarrhythmics. Selected 
adjustments in women: age and post-index event treatments – antiplatelets, class I/III 
antiarrhythmics and ACE inhibitors. Selected adjustments in STEMI: sex, prior AMI, on-
admission triglycerides and post-index event treatments – antiplatelets, ACE inhibitors, beta 
blockers, diuretics, class I/III antiarrhythmics. Selected adjustments in NSTEMI: age, on-
admission total cholesterol and post-index event antiplatelet use. 
 eGFR <60 (N=309) eGFR 60 (N=304) 
 OR (95% CI) P OR (95% CI) P 
Unadjusted SUA effects     
SUA by 50 mol/l 1.18 (1.07-1.32) 0.001 0.97 (0.74-1.27) 0.833 
Hyperuricemia vs. normal SUA 2.75 (1.55-4.96) <0.001 1.14 (0.17-4.40) 0.868 
Adjusted SUA effects     
SUA by 50 µmol/l 1.24 (1.08-1.44)* 0.003 1.02 (0.74-1.36)** 0.890 
Hyperuricemia vs. normal SUA 3.18 (1.49-7.03)* 0.003 1.46 (0.20-6.69** 0.659 
*Adjustments, default: sex, on-admission creatinine, lag-time symptoms-admission, prior symptomatic 
chronic heart failure (p<0.05); selected (all p<0.05): age, post-index event treatments (till day 30 or 
death, whichever first) – antiplatelets, ACE inhibitors, antiarrhythmics, diuretics. 
**Adjustments, default: sex, on-admission creatinine, lag-time symptoms-admission, prior symptomatic 
chronic heart failure; selected (all p<0.05): prior acute myocardial infarction, post-index event 
treatments (till day 30 or death, whichever first) – antiplatelets, beta-blockers. 
Table 5. Univariate and multivariate effects of SUA on 30-day mortality in AMI patients 
with eGFR <60 mL/min/1.73 m2 or 60 mL/min/1.73 m2 (based on the cohort described in 
Car&Trkulja 2009). 
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Fig. 7. Effect of SUA on 30-day mortality in AMI patients with on-admission eGFR <60 
mL/min/1.73 m2 or 60 mL/min/1.73 m2 (based on the cohort described in Car&Trkulja 
2009). Estimated probability of dying (A) and proportions of patients who died in the two 
subgroups in respect to SUA level (B). Vertical lines in A depict cut-off values of 
hyperuricemia in men and women.  
2.3 Prediction of long-term outcomes 
Prediction of medium- and long-term outcomes after AMI based on a single-point value of 
SUA may not be as straightforward as prediction of short-term outcomes. Namely, SUA levels 
may oscillate and change over time due to nutritional changes, habits (e.g., alcohol 
consumption, smoking) and effects of drugs, not only uricosuric or XO- inhibiting drugs, but 
also drugs commonly used in post-AMI patients, like thiazide diuretics or angiotensin receptor 
blockers. None of the studies has considered SUA as a time-varying variable. With this 
limitation acknowledged, all studies that reported on medium- or long-term outcomes after 
AMI (Table 2) consistently indicated independent unfavorable effects of SUA, either as a 
continuous variable or as “hyperuricemia”, on mortality or other markers of poor outcomes 
after AMI. Kojima (Kojima et al., 2005) additionally noticed that a combination of high SUA 
and high(er) Killip class was particularly unfavorable in long-term. Similarly, Bae (Bae et al. 
2011) showed the additive increase in risk between hyperuricemia and higher levels of NT-
ProBNP. Both results actually depict the combination of a failing heart and hyperuricemia as 
ominous. Indirectly, these observations are in line with those suggesting that the effects of high 
SUA might be particularly expressed in patients with a reduced renal function – eventually, 
hemodynamic consequences of a failing heart would lead to a reduced renal function. 
3 Conclusions and considerations for the future research 
There is a sound mechanistic rationale to support a view that a condition characterized by 
increased SUA, regardless of whether SUA is viewed as a direct “pathogen” or a (mere) 
marker of some other underlying processes, might be detrimental for acute AMI patients. 
Clinical observations accumulated over the past 5-6 years strongly support a view that SUA 
should be taken into account in the process of risk stratification in AMI patients. Moreover, 
there are sound indications of a possibility that it could also be a useful therapeutic target. 
However, larger-scale prospective studies are needed to precisely isolate and quantify the 
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“SUA” effect, overall, and in different settings – AMI types, reperfusion procedures, renal 
function. Since SUA is closely associated with various other risk factors in AMI patients, the 
usual approach of prognostic studies based on regression analysis might not be able to meet 
this goal. Therefore, data mining techniques might be a valuable tool to identify clusters 
and/or direct and mediated relationships between different risk factor and AMI outcomes 
that would improve our risk-stratification methodology. 
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